Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of V212 in adults with solid tumors or hematologic malignancies
2010-023156-89Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2010
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in herpes zoster (HZ) comparing V212 with Placebo (2 arms). Primary endpoints: Incidence of herpes zoster and Safety and tolerability of V212. Started Dec 2010; status: completed.
02
Drugs
zoster vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2010-023156-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023156-89.